longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Royalty Pharma PLC - CL

RPRX

58.4100.88% ( -0.520 )
Closed: Sep 18, 16:00:01 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 41.36, within the reasonable range, cheaper than 21.86% of the time in the past 5 years, and the industry ranks 50/257, the industry Median -1.31.

41.36xP/E
$58.41Stock price
$1.41Earnings per share
41.36xP/E
Stock price$58.41Earnings per share$1.41

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
28.55x
Typical range
18.60x–43.03x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
LLYUSEli Lilly
40.63x53.26%$1.09T
RPRXUSRoyalty Pharma PLC - CL
41.36x77.88%$33.59B
LQDAUSLiquidia Tech
43.19x476.41%$5.99B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.